G. Escobar and M. Lindsey, Multi-Analyte Profiling of Post-Myocardial Infarction Plasma 459 Samples, FASEB J, vol.21, issue.74611, pp.460-461, 2007.

N. Delaleu, H. Immervoll, J. Cornelius, and R. Jonsson, Biomarker profiles in serum and saliva of experimental Sj??gren's syndrome: associations with specific autoimmune manifestations, Arthritis Research & Therapy, vol.10, issue.1, pp.22-464, 2008.
DOI : 10.1186/ar2375

S. Kay, A. Fiszbein, and L. Opler, The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia, Schizophrenia Bulletin, vol.13, issue.2, pp.261-276, 1987.
DOI : 10.1093/schbul/13.2.261

P. Bossuyt, J. Reitsma, D. Bruns, C. Gatsonis, P. Glasziou et al., Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD Initiative, Clinical Chemistry, vol.49, issue.1, pp.1-6, 2003.
DOI : 10.1373/49.1.1

Y. Benjamini, Y. Hochberg, B. Seaton, G. Goldstein, D. Allen et al., Controlling the false discovery rate: a practical and powerful 473 approach to multiple testing Sources of heterogeneity in schizophrenia: the role of 476 neuropsychological functioning Neuropsychological function in euthymic patients 479 with bipolar disorder, J Roy Statist Soc Ser B Neuropsychol Rev Br J Psychiatry, vol.57, issue.480, pp.289-300, 1995.

M. Raja and A. Azzoni, Asperger???s disorder in the emergency psychiatric setting, General Hospital Psychiatry, vol.23, issue.5, pp.285-293, 2001.
DOI : 10.1016/S0163-8343(01)00155-4

W. Fleischhacker, Negative symptoms in patients with schizophrenia with special reference 485 to the primary versus secondary distinction, Encephale, vol.26, issue.1, pp.12-14, 2000.

E. Domenici, D. Wille, F. Tozzi, I. Prokopenko, S. Miller et al., Plasma Protein Biomarkers for Depression and Schizophrenia by Multi Analyte Profiling of Case-Control Collections, PLoS ONE, vol.5, issue.2, pp.9166-490
DOI : 10.1371/journal.pone.0009166.s008

W. Fessel and G. Solomon, Psychosis and systemic lupus erythematosus: a review of the 492 literature and case reports, Calif Med, vol.92, issue.493, pp.266-270, 1960.

R. Goldberg, Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and 495 imbalanced coagulation in development of diabetes and its complications, J Clin Endocrinol, vol.496, issue.497, pp.3171-3182, 2009.

A. Volp, A. Rde, C. Costa, N. Minim, V. Stringueta et al., Inflammation 499 biomarkers capacity in predicting the metabolic syndrome], Arq Bras Endocrinol Metabol, vol.500, issue.501, pp.537-549, 2008.

N. Muller, M. Riedel, M. Schwarz, and R. Engel, Clinical effects of COX?2 inhibitors on cognition in schizophrenia, European Archives of Psychiatry and Clinical Neuroscience, vol.11, issue.2, pp.149-151, 2005.
DOI : 10.1007/s00406-004-0548-4

P. Guest, L. Wang, L. Harris, K. Burling, Y. Levin et al., Increased levels of circulating 506 insulin-related peptides in first onset, antipsychotic naïve schizophrenia patients

T. Sato, H. Hanyu, K. Hirao, H. Kanetaka, H. Sakurai et al., Efficacy of PPAR-gamma agonist 510 pioglitazone in mild Alzheimer disease, Neurobiol Aging, vol.512, issue.511, p.29, 2009.

T. Baptista, N. Rangel, V. Fernandez, E. Carrizo, E. Fakih et al., Metformin as an 513 adjunctive treatment to control body weight and metabolic dysfunction during olanzapine 514 administration: a multicentric, double-blind, placebo-controlled trial, Schizophr Res, vol.93, issue.517, pp.1-3, 2007.

D. Henderson, X. Fan, B. Sharma, P. Copeland, C. Borba et al., A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with Schizophrenia, Acta Psychiatrica Scandinavica, vol.56, issue.suppl. B, pp.457-465, 2009.
DOI : 10.1111/j.1600-0447.2008.01325.x

J. Rybakowski, A. Wykretowicz, A. Heymann-szlachcinska, and H. Wysocki, Impairment of 522 endothelial function in unipolar and bipolar depression, Biol Psychiatry, vol.60, issue.524, pp.523-889, 2006.

L. Santos and E. Morand, Macrophage migration inhibitory factor: A key cytokine in RA, SLE and atherosclerosis, Clinica Chimica Acta, vol.399, issue.1-2, pp.1-7, 2009.
DOI : 10.1016/j.cca.2008.09.014

A. Burger-kentischer, H. Goebel, R. Seiler, G. Fraedrich, H. Schaefer et al., Expression of Macrophage Migration Inhibitory Factor in Different Stages of Human Atherosclerosis, Circulation, vol.105, issue.13, pp.1561-1566, 2002.
DOI : 10.1161/01.CIR.0000012942.49244.82

C. Chung, I. Avalos, A. Oeser, T. Gebretsadik, A. Shintani et al., High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors, Annals of the Rheumatic Diseases, vol.66, issue.2, pp.208-214, 2007.
DOI : 10.1136/ard.2006.054973

J. Wajed, Y. Ahmad, P. Durrington, and I. Bruce, Prevention of cardiovascular disease in systemic 542 lupus erythematosus--proposed guidelines for risk factor management, Rheumatology, vol.543, issue.544, pp.7-12

D. Hert, M. Van-winkel, R. Van-eyck, D. Hanssens, L. Wampers et al., Prevalence of 546 diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course 547 of the illness: a cross-sectional study, Clinical Practice and Epidemiology in Mental Health, vol.2, issue.1, pp.14-548, 2006.
DOI : 10.1186/1745-0179-2-14

S. Shoelson, J. Lee, and A. Goldfine, Inflammation and insulin resistance, J Clin Invest, vol.550, issue.551, pp.116-1793, 2006.

J. Steiner, M. Walter, P. Guest, A. Myint, K. Schiltz et al., Elevated S100B levels in schizophrenia are associated with insulin resistance, Molecular Psychiatry, vol.169, issue.1, pp.3-4
DOI : 10.1016/j.schres.2006.02.009

S. Prabakaran, J. Swatton, M. Ryan, S. Huffaker, J. Huang et al., Mitochondrial 556 dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative 557 stress, Mol Psychiatry, vol.9, issue.643, pp.684-697, 2004.

N. Uranova, I. Zimina, O. Vikhreva, N. Krukov, V. Rachmanova et al., 560 Ultrastructural damage of capillaries in the neocortex in schizophrenia, World J Biol Psychiatry, vol.561, issue.562, pp.567-578

J. Rybakowski and R. Weterle, Niacin test in schizophrenia and affective illness, Biological Psychiatry, vol.29, issue.8, pp.834-836, 1991.
DOI : 10.1016/0006-3223(91)90202-W

J. Morrow, J. Awad, J. Oates, and L. Roberts, Identification of skin as a major site of 567 prostaglandin D2 release following oral administration of niacin in humans, J Invest Dermatol, vol.568, issue.570, pp.812-815, 1992.

S. Smesny, S. Klemm, M. Stockebrand, S. Grunwald, U. Gerhard et al., Endophenotype properties of niacin sensitivity as marker of impaired prostaglandin signalling in Schizophrenia, Prostaglandins, Leukotrienes and Essential Fatty Acids, vol.77, issue.2, pp.79-85, 2007.
DOI : 10.1016/j.plefa.2007.08.006

J. Steiner, M. Walter, M. Wunderlich, H. Bernstein, B. Panteli et al., A new 575 pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its 576 scavenger soluble RAGE Early 579 detection and treatment of schizophrenia: how early?, Biol Psychiatry Jun Acta Psychiatr Scand, vol.15, issue.580429, pp.1107-1110, 2006.

. Dr, Erin Ingudomnukul for their participation in sample characterization and collection. Thanks to all 591 members of the Bahn Laboratory for discussions, help, and encouragement. Most of all, thanks to all 592 patients and healthy volunteers for their selfless donation of samples used in this study